TD Cowen analyst Tyler Van Buren initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and no price target The company’s pipeline, which will soon have nine clinical-stage programs , represents the best of targeted oncology, the analyst tells investors in a research note. The firm believes Ideaya’s lead combination drug candidate of darovasertib plus crizotinib should launch in 2026 in metastatic uveal melanoma with a high likelihood of success in neoadjuvant.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences
- Ideaya Biosciences resumed with a Neutral at Goldman Sachs
- Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital
- IDEAYA Biosciences Appoints New Chief Financial Officer
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls